Navigation Links
Positive Results for Second-Generation Taxus Liberte Coronary Stent,System Highlighted in Journal of American College of Cardiology

ent for the control group (p=0.83) were maintained at 12 months. In addition, nine-month stent thrombosis rates for both groups were low and similar for the TAXUS Liberte Stent (0.8 percent) and control stent (0.7 percent, p=1.0).

"ATLAS clinical outcomes highlight that despite more complex lesions, the TAXUS Liberte Stent performed extremely well and achieved similar rates of death, myocardial infarction and repeat procedures compared to an historical TAXUS Express control," said Mark Turco, M.D., FACC, FSCAI, Director of the Center for Cardiac and Vascular Research, Washington Adventist Hospital, Takoma Park, Maryland, and co-principal investigator of the TAXUS ATLAS trial.

Data reported in the JACC article showed the TAXUS Liberte Stent was associated with significantly shorter procedural times. The study documented shorter average procedure times of 47.8 minutes for TAXUS Liberte Stent versus 53.0 minutes in the control arm (p=0.0052). The need to use additional stents due to procedural complications was reduced by nearly 50 percent in the TAXUS Liberte Stent group (3.1 percent) versus control (6.0 percent) (p=0.0038).

"The TAXUS Liberte Stent represents the latest innovation of our drug-eluting stent pipeline and we are pleased that the TAXUS ATLAS results confirm its positive performance," said Paul LaViolette, Chief Operating Officer of Boston Scientific. "It is also further testament to the leadership of Boston Scientific that we are able to take a proven drug like paclitaxel and successfully transition it to an even more deliverable platform such as the Liberte Stent."

The Company received the CE Mark for the TAXUS Liberte stent in Europe and other international markets in September 2005, and it is currently the market-leading drug-eluting stent outside the United States. The TAXUS Liberte stent is currently pending approval by the U.S. Food and Drug Administration and is not available for sale in the United States.

Boston
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Protox Announces Positive Clinical Data from Prostate Cancer Study
5. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
6. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis

Post Your Comments:
(Date:11/25/2009)...wire-FirstCall/--Pharmasset,Inc.(Nasdaq: VRUS ),ac...ering,developingandcommercializingnoveldrugstotrea...calyearendedSeptember30,2009.AtSeptember30,2009Pha...ortterminvestments. ,, PipelineUpdateand2009Hi..., InlateNovember2009,anindependentDataMonitoring...
(Date:11/25/2009)...--BioTrendsResearchGroup,Inc.releasedWave1ofits L...ti-phasesyndicatedmarketresearchprojecttrackingthe...launchthroughthefirstsixmonthsofavailability.Eachw...5uniqueDermatologistsandqualitativeinformationfrom...bstaclestouse,typicalpatienttypes,productperceptio...
(Date:11/25/2009)...swire-USNewswire/--RemediumTechnologiesInc.,acompa...leeding,wonfirstprizeand$10,000intheMostPromisingS...9,companyofficialsannouncetoday. ,, Selectedfro...ampitchedtheirinventionattheGSCSecuritySummitconfe...um( www.remediumtechnologies.com )isdevelopingahig...
Breaking Medicine Technology:Pharmasset Reports Fiscal Year End 2009 Financial Results 2Pharmasset Reports Fiscal Year End 2009 Financial Results 3Pharmasset Reports Fiscal Year End 2009 Financial Results 4Pharmasset Reports Fiscal Year End 2009 Financial Results 5Pharmasset Reports Fiscal Year End 2009 Financial Results 6Pharmasset Reports Fiscal Year End 2009 Financial Results 7Pharmasset Reports Fiscal Year End 2009 Financial Results 8Despite Managed Care Obstacles, Interest and Anticipated Use of Centocor Ortho-Biotech's New Psoriasis Agent Stelara (ustekinumab) is High 2Remedium Technologies Wins Most Promising Security Idea at Global Security Challenge 2009 with Blood-Clotting Foam 2Remedium Technologies Wins Most Promising Security Idea at Global Security Challenge 2009 with Blood-Clotting Foam 3BioFlu Could This Be The Natural Defence Against Swine Flu 3F 54947 1BioFlu Could This Be The Natural Defence Against Swine Flu 3F 54947 2BioFlu Could This Be The Natural Defence Against Swine Flu 3F 54947 3Synthesis and Purification of Peptide Libraries Innovative Approaches 13634 1Synthesis and Purification of Peptide Libraries Innovative Approaches 13634 2Florida Spine Surgeon Alfred Bonati M D Announces Results of National Poll Showing America 26apos 3Bs Doctors Oppose a Government Run Health Care Pl 54942 1Florida Spine Surgeon Alfred Bonati M D Announces Results of National Poll Showing America 26apos 3Bs Doctors Oppose a Government Run Health Care Pl 54942 2
... NEW YORK--(BUSINESS WIRE)--Apr 4, 2007 - ImClone ...ers Squibb Company (NYSE:,BMY) announced today tha...ximab) combined with platinum-based chemotherapy,m...ival in patients,with recurrent and/or metastatic ...N). The randomized, multi-center study, known as,E...
... COLLEGEVILLE, Pa., April 03, 2007 /PRNewswire-Fi...yeth , provides comment on a,re- analysis of poole...,s Health Initiative (WHI) Study published today i... The pooled analysis,showed no apparent increase i...rmone therapy close to menopause. , The publicatio...
Other Medicine Technology:Survival Data Available from Erbitux Study in First-Line Treatment,of Advanced Head and Neck Cancer 2Survival Data Available from Erbitux Study in First-Line Treatment,of Advanced Head and Neck Cancer 3Survival Data Available from Erbitux Study in First-Line Treatment,of Advanced Head and Neck Cancer 4Survival Data Available from Erbitux Study in First-Line Treatment,of Advanced Head and Neck Cancer 5Survival Data Available from Erbitux Study in First-Line Treatment,of Advanced Head and Neck Cancer 6Survival Data Available from Erbitux Study in First-Line Treatment,of Advanced Head and Neck Cancer 7Survival Data Available from Erbitux Study in First-Line Treatment,of Advanced Head and Neck Cancer 8New Analysis of Data from WHI Provides Reassurance With Respect to,Coronary Heart Disease For Newly Menopausal Women Considering,Hormone Therapy 2New Analysis of Data from WHI Provides Reassurance With Respect to,Coronary Heart Disease For Newly Menopausal Women Considering,Hormone Therapy 3New Analysis of Data from WHI Provides Reassurance With Respect to,Coronary Heart Disease For Newly Menopausal Women Considering,Hormone Therapy 4New Analysis of Data from WHI Provides Reassurance With Respect to,Coronary Heart Disease For Newly Menopausal Women Considering,Hormone Therapy 5New Analysis of Data from WHI Provides Reassurance With Respect to,Coronary Heart Disease For Newly Menopausal Women Considering,Hormone Therapy 6
(Date:11/25/2009)...RONTOandCALGARY,Nov.25/PRNewswire/-SentinelleMedic...ing(MRI)coilsandsoftwareandCalgaryScientificInc.,a...introducedawebversionofAegis(TM)Breast4DAdvancedVi...isthefirsttrulyzero-footprintWebclientbasedmedical...Web(TM)platformallowsforzero-footprintaccess-requi...
(Date:11/25/2009)...LVERSPRING,Md.,Nov.25/PRNewswire-USNewswire/--Anar...forDrugEvaluationandResearch,titled"ADifficultBala...theNov.26,2009issueofTheNewEnglandJournalofMedicin...h/20090824/FDALOGO ) ,, Inthearticle,Woodcockdi...inmedicationforthosewhoneeditandmanagingtheriskspo...
(Date:11/25/2009)...roadPoliticalEndorsements,Business,andPressJoinEff...e-USNewswire/--Onceagain,theNationalBipolarFoundat...ndorsingtheir"Safe,tilStable"program,whichisnowbei...ipolardisorder.Today,theNationalBipolarFoundationr...PriorityMailfromtheLt.GovernorofLouisianaMitchLand...
(Date:11/25/2009)...uitous discovery that grew out of a collaboration ...ially offer hope to the nearly 10 million American... , Also known as hardening of the arteries, peri...latory problem in which narrowed arteries reduce b...d a red flag for vascular disease, heart attack an...
(Date:11/25/2009)... already used to fight rheumatoid arthritis, could... , WEDNESDAY, Nov. 25 (HealthDay News) -- A ... and rheumatoid arthritis now also shows some prom...1 diabetes. , The drug, rituximab (Rituxan), he...ulin, even though the disease had destroyed some o...
Breaking Medicine News(10 mins):Health News:Sentinelle Medical Inc. Introduces Aegis(TM) Web Powered By Calgary Scientific's PureWeb Technology 2Health News:Sentinelle Medical Inc. Introduces Aegis(TM) Web Powered By Calgary Scientific's PureWeb Technology 3Health News:First Time-Door is Open for Family Discussion of Bipolar Disorder 2Health News:First Time-Door is Open for Family Discussion of Bipolar Disorder 3Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 2Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 3Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 4Health News:Type 1 Diabetes May Have a New Foe 2Health News:Type 1 Diabetes May Have a New Foe 3
...acid supplements may slow cognitive decline in som... do not appear// to affect those with more advance... Alzheimer’s disease is a severely debilitati... according to background information in the articl...
... the ruling by Maryland's highest court a group of... state's medical// assistance program by Republica...The Court of Appeals voted unanimously that Ehrlic...ldren and pregnant women who were recent but legal...
...strict the use animals for the purpose of drug tes... are being developed by researchers at the Univers...130,000? as a financial grant. Gauging the ca...ety. Gentronix , a research company founded by ...
... a decline in the incidence of stroke in Perth, We...ding to new research// announced today by The Geor...l Scientific Meeting of the Stroke Society of Aust...tionally, over 53,000 strokes occur each year, of ...
...are provided by doctors and dentists according to ... which runs Barrowa€?s Furness General Hospital is...re Commission has roundly criticised the NHS servi...erformance of NHS in relation to government target...
...ut down the neo-natal intensive care unit of the R...immediate //effect was passed by the Philippine He...ts of the death of seven new born babies. Th...-natal sepsis”. . An inspection control commi...
Other Medicine News:Health News:Omega-3 May Slow Cognitive Decline in Some with Very Mild Alzheimer’ 2Health News:Health Care Benefits for Immigrants Favored by MD Court 2Health News:Grant Encourages Drug Testing Sans Animals 2Health News:Declining Incidence of stroke in Australia 2
...national reference laboratory and a worldwide lead...nt. ARUP offers an extensive test menu of highly c...atomic pathology. Owned by the University of Utah,... of the nation's university teaching hospitals and...
...national reference laboratory and a worldwide lead...nt. ARUP offers an extensive test menu of highly c...atomic pathology. Owned by the University of Utah,... of the nation's university teaching hospitals and...
...national reference laboratory and a worldwide lead...nt. ARUP offers an extensive test menu of highly c...atomic pathology. Owned by the University of Utah,... of the nation's university teaching hospitals and...
...national reference laboratory and a worldwide lead...nt. ARUP offers an extensive test menu of highly c...atomic pathology. Owned by the University of Utah,... of the nation's university teaching hospitals and...
Medicine Products: